Kura Oncology, Inc. — Form 10-Q Summary
Business context and reporting period
Kura Oncology is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined cancers. Its pipeline included clinical-stage ziftomenib and tipifarnib, preclinical-stage KO-2806, and discovery programs. The filing covers the three and six months ended June 30, 2022; financial statements are unaudited and prepared under U.S. GAAP.
The company had no approved products and generated no product-sales revenue. Its principal programs were ziftomenib for genetically defined acute myeloid leukemia, tipifarnib for selected solid-tumor and hematologic indications, and KO-2806 in IND-enabling studies.
Key financial metrics
| Metric | Three months ended June 30, 2022 | Three months ended June 30, 2021 | Six months ended June 30, 2022 | Six months ended June 30, 2021 |
|---|---|---|---|---|
| Product revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $24.3 million | $21.1 million | $45.2 million | $41.4 million |
| General and administrative expense | $11.1 million | $12.6 million | $22.9 million | $23.1 million |
| Total operating expenses | $35.3 million | $33.6 million | $68.1 million | $64.5 million |
| Net loss | $34.8 million | $33.7 million | $67.2 million | $64.4 million |
| Net loss per share | $0.52 | $0.51 | $1.01 | $0.97 |
| Net cash used in operating activities | Not separately reported | Not separately reported | $62.5 million | $56.6 million |
There was no meaningful revenue or profit margin because the company had no product sales and remained loss-making. Other income, primarily interest income, was $0.6 million in the second quarter and $0.9 million for the first six months. Interest expense was zero in 2022 following repayment of the term loan in May 2021.
- Cash and cash equivalents at June 30, 2022: $39.3 million.
- Short-term investments: $411.0 million.
- Total cash, cash equivalents and short-term investments: $450.3 million.
- Total assets: $471.4 million; total liabilities: $21.9 million; stockholders’ equity: $449.5 million.
- Accumulated deficit: $500.2 million.
- Cash, cash equivalents and restricted cash declined by $51.4 million during the first six months of 2022.
- Operating cash use was partly offset by $8.1 million of investing cash inflow, primarily from maturities of marketable securities, and $3.0 million of proceeds from equity-plan stock issuances.
- The company had $5.9 million of operating lease liabilities and approximately $0.2 million of restricted cash securing a standby letter of credit.
Material changes versus the prior comparable period
- Second-quarter research and development expense increased $3.2 million, or approximately 15%, to $24.3 million. The increase primarily reflected higher ziftomenib trial costs, discovery activity for KO-2806, personnel costs and share-based compensation.
- Six-month research and development expense increased $3.8 million to $45.2 million. Ziftomenib-related costs increased $3.3 million, while tipifarnib-related costs decreased $7.6 million as certain clinical, manufacturing and companion-diagnostic activities declined.
- General and administrative expense decreased $1.5 million in the second quarter and $0.2 million for the six-month period, primarily because of lower professional-services and personnel costs.
- Second-quarter net loss increased $1.1 million, and six-month net loss increased $2.9 million, reflecting higher operating expenses.
- Operating cash use increased $5.9 million year over year to $62.5 million, while investing activities shifted from a $223.4 million use of cash in 2021 to an $8.1 million source of cash in 2022 because of the timing of marketable-security purchases and maturities.
- Unrealized losses on marketable securities and foreign currency were $6.0 million for the first six months of 2022 versus $0.4 million in the prior-year period, primarily reflecting interest-rate-related changes in investment fair values.
Guidance, outlook, commentary, risks and unusual items
Management stated that existing cash, cash equivalents and short-term investments were expected to fund operating expenses and capital requirements through 2024 based on current plans. The company also stated that it will require substantial additional financing and had no committed external source of funds. A February 2022 ATM facility permits sales of up to $150.0 million of common stock, but no shares had been sold under the facility as of the filing.
- KOMET-001 enrollment in the ziftomenib Phase 1b expansion cohorts was complete. Management expected to identify the recommended Phase 2 dose and report topline data in the second half of 2022.
- The FDA lifted a partial clinical hold on KOMET-001 in January 2022 after agreement on a mitigation strategy for differentiation syndrome. The hold followed a Grade 5 serious adverse event potentially associated with differentiation syndrome.
- The company expected to initiate the KURRENT-LUNG Phase 1 trial of tipifarnib plus osimertinib in EGFR-mutated non-small-cell lung cancer in the third quarter of 2022.
- The company expected to submit an IND for KO-2806 in the fourth quarter of 2022.
- KURRENT-HN, evaluating tipifarnib plus Novartis’s alpelisib in biomarker-defined head and neck cancer cohorts, was ongoing. The filing states that the first patient in the HRAS-overexpression cohort was dosed in August 2022, after the reporting period.
- Key risks include clinical-trial failure or delay, safety events, regulatory holds or non-approval, difficulty enrolling genetically selected patients, dependence on third-party manufacturers and CROs, companion-diagnostic development, COVID-19-related disruptions, competition, intellectual-property challenges and the need for additional capital.
- The company may be required to make up to approximately $80.0 million in milestone payments, plus sales royalties, under in-license agreements if specified regulatory and commercial milestones are achieved.
- No material legal proceedings were reported, and management concluded that disclosure controls and procedures were effective as of June 30, 2022.
Most important facts for investors to verify
- Whether ziftomenib topline data and recommended dose were reported as projected in the second half of 2022, and the implications of the prior differentiation-syndrome event.
- Whether the company’s projected cash runway through 2024 remains supportable after subsequent clinical, manufacturing and operating expenditures.
- The pace of cash burn and whether the $150.0 million ATM facility or other financing has been used, including potential shareholder dilution.
- Clinical enrollment, efficacy and safety results for ziftomenib and tipifarnib, including the registration-directed AIM-HN trial.
- Regulatory progress for KO-2806 and the KURRENT-LUNG and KURRENT-HN programs.
- Availability and regulatory readiness of required companion diagnostics and third-party drug supplies, including alpelisib and potential combination partners.